Even though the introduction of newer glucose-lowering agents such as GLP-1 agonists and SGLT2 inhibitors improves the management of DM, they are usually prescribed as a second-line therapy in the case of uncontrolled diabetes. Here, SLC5A2 is linked to diabetes mellitus.